Evidence map›Paper›PMID 41802098›Full record

ReviewCardiorenal medicine2026

A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury.

Farah Yasmin, Sharjeel Ahmad, Adina Jabeen, Abdul Moeed, Muhammad Sohaib Asghar, Afsana Ansari Shaik, Mohammed Mahmmoud Fadelallah Eljack, M Chadi Alraies

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Farah YasminDow University of Health Sciences, Karachi, Pakistan.
Sharjeel AhmadAga Khan University Hospital, Karachi, Pakistan.
Adina JabeenDow University of Health Sciences, Karachi, Pakistan.
Abdul MoeedDow University of Health Sciences, Karachi, Pakistan.
Muhammad Sohaib AsgharAdventHealth Sebring, Sebring, Florida, USA.
Afsana Ansari ShaikMayo Clinic Rochester, Rochester, Minnesota, USA.
Mohammed Mahmmoud Fadelallah EljackUniversity of Khartoum, Faculty of Science.Ad-Dwayem, Khartoum, Sudan, m.mahmmoud96@gmail.com.
M Chadi AlraiesDetroit Medical Centre, Detroit, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenin-angiotensin system (RAS) inhibitors, including ACE inhibitors, ARBs, and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential in managing cardiovascular and renal diseases. SUMMARY: The purpose of this narrative review was to comprehensively evaluate the cardiovascular outcomes associated with the use of RAS inhibitors in patients who have experienced acute kidney injury (AKI). The study highlighted cardiovascular complications of AKI, role of renin-angiotensin inhibitors for cardioprotection post-AKI, reviewed clinical considerations for RAS inhibitor use post-AKI to prevent cardiovascular complications, and discussed mechanistic basis of RAS inhibitors in post-AKI cardioprotection as well as cardiovascular safety concerns of RAS inhibitors post-AKI. KEY MESSAGES: By highlighting areas for future research, this review intended to stimulate further studies that will ultimately enhance patient care and outcomes.

Indexed as

Acute Kidney InjuryAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardio-Renal SyndromeCardiovascular DiseasesRenin-Angiotensin SystemHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAldosterone synthesisCardiorenal syndromeCardiovascular diseaseRegulation of blood pressureRenal metabolism

Identifiers

PMID41802098
PMCPMC13221169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.